Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma

被引：0
|
作者：
Zhang, Yanping
Peng, Guangyong
Hsueh, Eddy C.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-375
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
375
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
    Rittler, Dominika
    Molnar, Eszter
    Baranyi, Marcell
    Garay, Tamas
    Hegedus, Luca
    Aigner, Clemens
    Tovari, Jozsef
    Timar, Jozsef
    Hegedus, Balazs
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 18
  • [2] Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer
    Roper, Jatin
    Sinnamon, Mark J.
    Coffee, Erin M.
    Belmont, Peter
    Keung, Lily
    Georgeon-Richard, Larissa
    Wang, Wei Vivian
    Faber, Anthony C.
    Yun, Jihye
    Yilmaz, Oemer H.
    Bronson, Roderick T.
    Martin, Eric S.
    Tsichlis, Philip N.
    Hung, Kenneth E.
    [J]. CANCER LETTERS, 2014, 347 (02) : 204 - 211
  • [3] Enhanced cytotoxic activity of BRAF, MEK and PI3K inhibition with combination CDK4/6 inhibition in melanoma cells
    Zhang, Yanping
    Peng, Guangyong
    Hsueh, Eddy C.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [4] Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
    Sinik, Lenka
    Minson, Katherine A.
    Tentler, John J.
    Carrico, Jacqueline
    Bagby, Stacey M.
    Robinson, William A.
    Kami, Rotem
    Burstyn-Cohen, Tal
    Eckhardt, S. Gail
    Wang, Xiaodong
    Frye, Stephen, V
    Earp, H. Shelton
    DeRyckere, Deborah
    Graham, Douglas K.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 278 - 288
  • [5] Inhibition of wildtype PI3Kα signaling is required for durable efficacy in PI3Kα mutant cancer cells due to robust reactivation of wild-type PI3Kα signaling
    MacDougall, John R.
    Zhong, Mengqi
    Merritt, Hanne
    Del Cid, Joselyn S.
    Bradley, John
    Mak, Raymond
    Dhawan, Neil
    Chen, Wei
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [6] Inhibition of BRAF and MEK in BRAF-mutant melanoma
    Smalley, Keiran S. M.
    Sondak, Vernon K.
    [J]. LANCET, 2015, 386 (9992): : 410 - 412
  • [7] Elucidating the role of PI3K lipid effectors in BRAF mutant melanoma
    Parkman, Gennie
    Cho, Joseph
    Holmen, Sheri
    McMahon, Martin
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [8] Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
    Francisco Meraz-Torres
    Heike Niessner
    Sarah Plöger
    Simon Riel
    Barbara Schörg
    Nicolas Casadei
    Manfred Kneilling
    Martin Schaller
    Lukas Flatz
    Boris Macek
    Thomas Eigentler
    Olaf Rieß
    Claus Garbe
    Teresa Amaral
    Tobias Sinnberg
    [J]. Journal of Experimental & Clinical Cancer Research, 43
  • [9] Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
    Meraz-Torres, Francisco
    Niessner, Heike
    Ploeger, Sarah
    Riel, Simon
    Schoerg, Barbara
    Casadei, Nicolas
    Kneilling, Manfred
    Schaller, Martin
    Flatz, Lukas
    Macek, Boris
    Eigentler, Thomas
    Riess, Olaf
    Garbe, Claus
    Amaral, Teresa
    Sinnberg, Tobias
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [10] BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
    Richman, Juliet
    Martin-Liberal, Juan
    Diem, Stefan
    Larkin, James
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (09) : 1285 - 1297
12345